AI Article Synopsis
- Scientists really need new ways to treat Alzheimer's disease (AD), which affects memory and thinking.
- A protein called Dyrk1a is linked to important problems in AD, and they studied what happens when they stop Dyrk1 in special mice that show signs of AD.
- The treatment helped the mice think better and lowered harmful proteins in their brains, suggesting that targeting Dyrk1 could be a promising way to help treat Alzheimer's disease.
Article Abstract
There is an urgent need for the development of new therapeutic strategies for Alzheimer's disease (AD). The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between two key proteins involved in AD pathogenesis. Furthermore, Dyrk1a is upregulated in postmortem human brains, and high levels of Dyrk1a are associated with mental retardation. Here, we sought to determine the effects of Dyrk1 inhibition on AD-like pathology developed by 3xTg-AD mice, a widely used animal model of AD. We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg) mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for eight weeks. During the last three weeks of treatment, we tested the mice in a battery of behavioral tests. The brains were then analyzed for the pathological markers of AD. We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice. These effects were associated with a reduction in amyloid-β (Aβ) and tau pathology. Mechanistically, Dyrk1 inhibition reduced APP and insoluble tau phosphorylation. The reduction in APP phosphorylation increased its turnover and decreased Aβ levels. These results suggest that targeting Dyrk1 could represent a new viable therapeutic approach for AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595697 | PMC |
| http://dx.doi.org/10.1111/acel.12648 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.
J Med Chem
October 2024
Division of Drug Discovery and Development, Department of Pharmacology and Toxicology, College of Pharmacy The University of Arizona, Tucson, Arizona 85721, United States.
Small-molecule-induced protein degradation has emerged as a promising pharmacological modality for inactivating disease-relevant protein kinases. DYRK1A and DYRK1B are closely related protein kinases that are involved in pathological processes such as neurodegeneration, cancer development, and adaptive immune homeostasis. Herein, we report the development of the first DYRK1 proteolysis targeting chimeras (PROTACs) that combine a new ATP-competitive DYRK1 inhibitor with ligands for the E3 ubiquitin ligase component cereblon (CRBN) to induce ubiquitination and subsequent proteasomal degradation of DYRK1A and DYRK1B.
View Article and Find Full Text PDFAddendum: A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase.
Nat Commun
August 2024
Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
The Nitro Group Reshapes the Effects of Pyrido[3,4-]quinazoline Derivatives on DYRK/CLK Activity and RNA Splicing in Glioblastoma Cells.
Cancers (Basel)
February 2024
Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Serine-threonine protein kinases of the DYRK and CLK families regulate a variety of vital cellular functions. In particular, these enzymes phosphorylate proteins involved in pre-mRNA splicing. Targeting splicing with pharmacological DYRK/CLK inhibitors emerged as a promising anticancer strategy.
View Article and Find Full Text PDFGenetic Analysis of Filamentation by the Iron Chelator BPS Reveals a Role for a Conserved Kinase-WD40 Protein Pair.
J Fungi (Basel)
January 2024
Department of Molecular Microbiology, B. Rappaport Faculty of Medicine, Technion-I.I.T., Haifa 31096, Israel.
is a major human pathogenic fungus that is distinguished by its capability to switch from a yeast to a hyphal morphology under different conditions. Here, we analyze the cellular effects of high concentrations of the iron chelator bathophenanthroline disulfonate (BPS). BPS inhibits cellular growth by withholding iron, but when iron chelation is overcome by the addition of hemoglobin as an iron source, the cells resume growth as hyphae.
View Article and Find Full Text PDFQuantitative Phosphoproteomics Reveals the Requirement of DYRK1-Mediated Phosphorylation of Ion Transport- and Cell Junction-Related Proteins for Notochord Lumenogenesis in Ascidian.
Cells
March 2023
Fang Zongxi Center, MoE Key Laboratory of Marine Genetics and Breeding, College of Marine Life Sciences, Ocean University of China, Qingdao 266003, China.
Article Synopsis
- The study focuses on the role of DYRK1 kinase in notochord development and lumen formation in ascidians, revealing that blocking its activity impairs these processes.
- Through phosphoproteomics, researchers identified 1,065 notochord-specific phosphoproteins, with 428 that were differently phosphorylated upon DYRK1 inhibition, highlighting their involvement in vital cellular functions.
- Further analysis demonstrated that mutations in specific phosphosites of key protein families (like SLC, RAB, and TJP) led to defects in lumen formation, indicating the importance of phosphorylation in regulating cellular processes related to notochord development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!